CoChat

Global, regional, and national burden of glucose-6-phosphate dehydrogenase (G6PD) deficiency from 1990 to 2021: a systematic analysis of the global burden of disease study 2021

Yu, Zhengyu, Xiong, Qiang, Wang, Zhongwang, Li, Linfeng, Niu, Ting · 2025 · Frontiers in Genetics
Cited by 21

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Background: Glucose-6-phosphate dehydrogenase (G6PD) deficiency remains a significant global health burden, particularly in malaria-endemic regions. Despite advances in diagnostic capabilities and treatment strategies, the prevalence and associated disability burden continue to evolve. This study provides a comprehensive assessment of the global, regional, and national burden of G6PD deficiency from 1990 to 2021, using the Global Burden of Disease (GBD) 2021 database. Methods: Data were retrieved from GBD 2021, covering 204 countries and territories. Prevalence, incidence, and years lived with disability (YLDs) were analyzed. Age-standardized rates (ASRs) and estimated annual percentage change (EAPC) were computed to assess trends over time. The relationship between socio-demographic index (SDI) and G6PD burden was examined using Spearman correlation analysis. Results: In 2021, global prevalence reached 443,326,869 cases, an 80.17% increase from 1990. The highest burden was observed in South Asia, accounting for 138,159,940 cases. The largest percentage increase in prevalence was in Andean Latin America (+291.96%). G6PD deficiency burden was negatively correlated with SDI, but high SDI regions exhibited higher prevalence than expected. Age- and sex-specific analysis revealed a higher burden in males, particularly in childhood and older age groups. Conclusion: This study underscores the growing burden of G6PD deficiency, with substantial regional disparities. The findings emphasize the need for improved screening programs, policy interventions, and resource allocation in low- and middle-income countries (LMICs). Continued surveillance is essential to mitigate the long-term health consequences of this disorder.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fgene.2025.1593728

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 27

  1. Arain, 2014, Prevention of Kernicterus in South Asia: role of neonatal G6PD deficiency and its identification, Indian J. Pediatr., 81, 599, 10.1007/s12098-014-1410-y · DOI
  2. Awab, 2021, Protective effect of Mediterranean-type glucose-6-phosphate dehydrogenase deficiency against Plasmodium vivax malaria, Elife, 10, 10, 10.7554/elife.62448 · DOI
  3. Chu, 2018, Primaquine-induced haemolysis in females heterozygous for G6PD deficiency, Malar. J., 17, 101, 10.1186/s12936-018-2248-y · DOI · Paper page
  4. Ciavarella, 2025, Quantifying Plasmodium vivax radical cure efficacy: a modelling study integrating clinical trial data and transmission dynamics, Lancet Infect. Dis, 10.1016/S1473-3099(24)00689-3 · DOI
  5. Clarke, 2017, Characterisation of the opposing effects of G6PD deficiency on cerebral malaria and severe malarial anaemia, Elife, 6, e15085, 10.7554/eLife.15085 · DOI
  6. Dore, 2021, The elderly with glucose-6-phosphate dehydrogenase deficiency are more susceptible to cardiovascular disease, J. Atheroscler. Thromb., 28, 604, 10.5551/jat.56531 · DOI
  7. Galatas, 2017, Heterogeneity of G6PD deficiency prevalence in Mozambique: a school-based cross-sectional survey in three different regions, Malar. J., 16, 36, 10.1186/s12936-016-1674-y · DOI
  8. Goyal, 2015, Newborn screening for G6PD deficiency: a 2-year data from North India, Indian J. Public Health, 59, 145, 10.4103/0019-557X.157537 · doi:10.4103/0019-557x.157537
  9. Kuupiel, 2020, Geographical accessibility to glucose-6-phosphate dioxygenase deficiency point-of-care testing for antenatal care in Ghana, Diagnostics (Basel), 10, 229, 10.3390/diagnostics10040229 · DOI
  10. Kwiatkowski, 2005, How malaria has affected the human genome and what human genetics can teach us about malaria, Am. J. Hum. Genet., 77, 171, 10.1086/432519 · DOI · Paper page
  11. LaRue, 2014, Comparison of quantitative and qualitative tests for glucose-6-phosphate dehydrogenase deficiency, Am. J. Trop. Med. Hyg., 91, 854, 10.4269/ajtmh.14-0194 · DOI · Paper page
  12. 2014, Reappraisal of known malaria resistance loci in a large multicenter study, Nat. Genet., 46, 1197, 10.1038/ng.3107 · DOI · Paper page
  13. Mukherjee, 2015, Glucose-6-phosphate dehydrogenase (G6PD) deficiency among tribal populations of India - country scenario, Indian J. Med. Res., 141, 516, 10.4103/0971-5916.159499 · DOI
  14. Pal, 2019, Evaluation of a novel quantitative test for glucose-6-phosphate dehydrogenase deficiency: bringing quantitative testing for glucose-6-phosphate dehydrogenase deficiency closer to the patient, Am. J. Trop. Med. Hyg., 100, 213, 10.4269/ajtmh.18-0612 · DOI · Paper page
  15. Pao, 2005, Neonatal screening for glucose-6-phosphate dehydrogenase deficiency, Indian J. Pediatr., 72, 835, 10.1007/BF02731109 · doi:10.1007/bf02731109
  16. Pukrittayakamee, 2024, Primaquine in glucose-6-phosphate dehydrogenase deficiency: an adaptive pharmacometric assessment of ascending dose regimens in healthy volunteers, Elife, 12, 10.7554/eLife.87318 · doi:10.7554/elife.87318
  17. Sadhewa, 2025, Performance of quantitative point-of-care tests to measure G6PD activity: an individual participant data meta-analysis, PLoS Negl. Trop. Dis., 19, e0012864, 10.1371/journal.pntd.0012864 · DOI
  18. Stykel, 2025, G6PD deficiency triggers dopamine loss and the initiation of Parkinson's disease pathogenesis, Cell Rep., 44, 115178, 10.1016/j.celrep.2024.115178 · DOI
  19. Sulistyaningrum, 2020, Prevalence of glucose 6-phosphate dehydrogenase variants in malaria-endemic areas of south central timor, eastern Indonesia, Am. J. Trop. Med. Hyg., 103, 760, 10.4269/ajtmh.19-0780 · DOI
  20. Tabatabaei, 2015, Prevalence of glucose-6-phosphate dehydrogenase (G6PD) deficiency in southeast Iran: implications for malaria elimination, J. Infect. Dev. Ctries., 9, 289, 10.3855/jidc.5572 · DOI
  21. Tang, 2024, Incidence trends of inherited anemias at the global, regional, and national levels over three decades, J. Epidemiol. Glob. Health, 14, 72, 10.1007/s44197-023-00170-9 · DOI
  22. Taylor, 2023, Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the Congo: a randomised, double-blind, placebo-controlled, non-inferiority trial, Lancet Infect. Dis., 23, 471, 10.1016/S1473-3099(22)00658-2 · DOI
  23. Watson, 2017, Modelling primaquine-induced haemolysis in G6PD deficiency, Elife, 6, e23061, 10.7554/eLife.23061 · DOI · Paper page
  24. Watson, 2019, Collider bias and the apparent protective effect of glucose-6-phosphate dehydrogenase deficiency on cerebral malaria, Elife, 8, e43154, 10.7554/eLife.43154 · DOI
  25. Xuan-Rong Koh, 2023, Prevalence and molecular heterogeneity of glucose-6-phosphate dehydrogenase (G6PD) deficiency in the Senoi Malaysian Orang Asli population, PLoS One, 18, e0294891, 10.1371/journal.pone.0294891 · doi:10.1371/journal.pone.0294891
  26. Zhou, 2024, Evaluating the relationship between Clinical G6PD enzyme activity and gene variants, PeerJ, 12, e16554, 10.7717/peerj.16554 · doi:10.7717/peerj.16554
  27. Zobrist, 2021, Evaluation of a point-of-care diagnostic to identify glucose-6-phosphate dehydrogenase deficiency in Brazil, PLoS Negl. Trop. Dis., 15, e0009649, 10.1371/journal.pntd.0009649 · DOI

Cited by

See all 21

Metadata

Authors
Yu, Z., Xiong, Q., Wang, Z., Li, L., & Niu, T.
Venue
Frontiers in Genetics
Published
2025-05-23
Volume
16
ISSN
1664-8021
Cited by
21
References
5

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.